Temsirolimus (Torisel, CCI-779, C15182, NSC-683864, D06068, 42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoyl)-rapamycin, CAS 162635-04-3), >99%

LC Laboratories' Product Number T-8040 - Temsirolimus (CCI-779, Torisel, CAS 162635-04-3), 99% - for research use only. Temsirolimus, a rapamycin (sirolimus) derivative, also known as CCI-779, is an mTOR inhibitor with anti-cancer activity. Antiangiogenic effects may contribute to the antitumor activity of temsirolimus observed in breast cancer. Temsirolimus showed synergistic in vivo antimyeloma effects in combination with dexamethasone in a xenograft model. In lymphoblasts from adult patients with acute lymphoblastic leukemia (ALL), cells treated with sirolimus showed an increase in apoptotic cells and a dramatic decrease in cell proliferation compared to untreated cells. Temsirolimus is able to reverse cisplatin resistance in small cell lung cancer cell lines selected for cisplatin resistance and in cell lines derived from patients who failed cisplatin therapy. Temsirolimus is the active ingredient in the drug sold under the trade name Torisel®. This drug has been approved in at least one country for use in patients with advanced renal (kidney) cell carcinoma. NOTE: The temsirolimus sold by LC Laboratories is NOT Torisel®, and is NOT for human use. Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.

• Supplier: LC Laboratories
• Product #: T-8040
• Sku #: T-8040-25mg